Predicting accelerated aggregation rates for monoclonal antibody formulations, and challenges for low-temperature predictions

RK Brummitt, DP Nesta, CJ Roberts - Journal of pharmaceutical sciences, 2011 - Elsevier
Nonnative aggregation is a common degradation route for therapeutic proteins. Control of
aggregate levels inherently requires control and/or prediction of aggregation rates at …
被引用次数：85 相关文章

Predicting accelerated aggregation rates for monoclonal antibody formulations, and challenges for low-temperature predictions.

RK Brummitt, DP Nesta, CJ Roberts - Journal of Pharmaceutical …, 2011 - europepmc.org
Nonnative aggregation is a common degradation route for therapeutic proteins. Control of
aggregate levels inherently requires control and/or prediction of aggregation rates at …

[引用][C] Predicting accelerated aggregation rates for monoclonal antibody formulations, and challenges for low-temperature predictions

RK Brummitt, DP Nesta, CJ Roberts - Journal of Pharmaceutical …, 2011 - cir.nii.ac.jp
Predicting accelerated aggregation rates for monoclonal antibody formulations, and challenges
for low-temperature predictions | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ …

Predicting accelerated aggregation rates for monoclonal antibody formulations, and challenges for low‐temperature predictions

RK Brummitt, DP Nesta, CJ Roberts - Journal of Pharmaceutical Sciences, 2011 - infona.pl
Nonnative aggregation is a common degradation route for therapeutic proteins. Control of
aggregate levels inherently requires control and/or prediction of aggregation rates at …

Predicting accelerated aggregation rates for monoclonal antibody formulations, and challenges for low‐temperature predictions

RK Brummitt, DP Nesta… - Journal of Pharmaceutical …, 2011 - Wiley Online Library
Nonnative aggregation is a common degradation route for therapeutic proteins. Control of
aggregate levels inherently requires control and/or prediction of aggregation rates at …

Predicting accelerated aggregation rates for monoclonal antibody formulations, and challenges for low-temperature predictions

RK Brummitt, DP Nesta, CJ Roberts - Journal of Pharmaceutical …, 2011 - jpharmsci.org
Nonnative aggregation is a common degradation route for therapeutic proteins. Control of
aggregate levels inherently requires control and/or prediction of aggregation rates at …

Predicting accelerated aggregation rates for monoclonal antibody formulations, and challenges for low-temperature predictions

RK Brummitt, DP Nesta… - Journal of …, 2011 - pubmed.ncbi.nlm.nih.gov
Nonnative aggregation is a common degradation route for therapeutic proteins. Control of
aggregate levels inherently requires control and/or prediction of aggregation rates at …

[引用][C] Predicting Accelerated Aggregation Rates for Monoclonal Antibody Formulations, and Challenges for Low-Temperature Predictions

RK BRUMMITT, DP NESTA… - Journal of …, 2011 - pascal-francis.inist.fr
Predicting Accelerated Aggregation Rates for Monoclonal Antibody Formulations, and
Challenges for Low-Temperature Predictions CNRS Inist Pascal-Francis CNRS Pascal and …